IP Library Granted Patent US 8,790,294
Granted Patent B2
US 8,790,294 · App. 13/613,620 · Granted Jul 29, 2014

Infusion pump system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,294
App. No.
13/613,620
Granted
Jul 29, 2014
Kind
B2
Abstract

Some embodiments of a portable infusion pump system can be configured to adjust the sensitivity of particular detectors or alert systems based (at least in part) on information received from a monitoring device. For example, a glucose monitoring device can communication with an infusion pump assembly used to supply insulin or another medication to a user. In such circumstances, the data received from the monitoring device can be used to adjust the sensitivity of an occlusion detection system.

Claims (26)

1. An insulin infusion pump system, comprising:

a portable pump housing that defines an internal space to receive an insulin medicine for dispensation to a user;

control circuitry configured to operate an occlusion detection system to detect a fluid condition in a flow path extending from the insulin medicine in the internal space to a user, the occlusion detection system having an adjustable sensitivity, wherein the control circuitry is configured to output an occlusion alarm to the user when an occlusion is detected in the flow path; and

a monitoring device configured to communicate glucose information to the control circuitry, the glucose information being indicative of a blood glucose level of the user,

wherein the sensitivity of the occlusion detection system is adjusted in response to the glucose information received by the control circuitry from the monitoring device.

2. The system of claim 1 , wherein the control circuitry is configured to adjust the sensitivity of the occlusion detection system when the glucose information received by the control circuitry from the monitoring device indicates that the blood glucose level of the user is outside of a predetermined range.

3. The system of claim 1 , wherein the sensitivity of the occlusion detection system is increased in response to glucose information received by the control circuitry that indicates the user's blood glucose level is greater than a predetermined value.

4. The system of claim 3 , wherein when the sensitivity of the occlusion detection system is increased, the control circuitry outputs an alarm via a user interface connected with the control circuitry to indicate a blood glucose level that is outside of a normal range.

5. The system of claim 4 , wherein when the sensitivity of the occlusion detection system is increased, the control circuitry outputs an alarm via the user interface to indicate a change to the occlusion detection system.

6. The system of claim 1 , wherein the sensitivity of the occlusion detection system is increased in response to glucose information received by the control circuitry that indicates the user's blood glucose level is rising at a rate greater than a predetermined rate.

7. The system of claim 6 , wherein when the sensitivity of the occlusion detection system is increased, the control circuitry outputs an alarm via a user interface to indicate a change to the occlusion detection system.

8. The system of claim 1 , wherein the sensitivity of the occlusion detection system is decreased in response to glucose information received by the control circuitry that indicates the user's blood glucose level is less than a predetermined value.

9. The system of claim 8 , wherein when the sensitivity of the occlusion detection system is decreased, the control circuitry outputs an alarm via a user interface to indicate a blood glucose level that is outside of a normal range.

10. The system of claim 1 , wherein the sensitivity of the occlusion detection system is decreased in response to glucose information received by the control circuitry that indicates the user's blood glucose level is decreasing at a rate greater than a predetermined rate.

11. The system of claim 10 , wherein when the sensitivity of the occlusion detection system is decreased, the control circuitry outputs an alarm via a user interface to indicate a change to the occlusion detection system.

12. The system of claim 1 , wherein the control circuitry is positioned in a controller housing that removably attaches to the pump housing, the control circuitry being in electrical communication with a pump drive system positioned in the pump housing when the controller housing is removably attached to the pump housing.

13. The system of claim 12 , wherein the control circuitry is connected with a user interface mounted to the controller housing that includes a display device and a plurality of buttons.

14. The system of claim 12 , wherein the controller housing and control circuitry are components of a reusable controller device and the pump housing and pump drive system are components of a disposable and nonreusable pump device having one or more structures that prevent reuse of the pump device after the insulin medicine is exhausted.

15. The system of claim 1 , wherein the flow path of the insulin medicine comprises a reservoir in which the insulin medicine is retained, at least a portion of a cap device that secures to the pump housing, and an infusion set tube that extends from the cap device to the user.

16. The system of claim 1 , wherein the occlusion detection system comprises at least one of a pressure transducer and a pressure switch to communicate signals to the control circuitry indicative of fluid pressure in the flow path of the insulin medicine.

17. The system of claim 1 , wherein the occlusion detection system comprises an optical sensor arranged proximate to the flow path of the insulin medicine.

18. The system of claim 1 , wherein the monitoring device comprises a portable housing wearable on the user's skin, a sensor shaft that penetrates into the user's skin, and a wireless communication device to transmit the glucose information to a wireless communication device of the control circuitry.

19. The system of claim 1 , wherein the pump housing at least partially houses a pump drive system to dispense the insulin medicine through the flow path to the user, and wherein the control circuitry is electrically connected to at least one component of the pump drive system so that the control circuitry is configured to activate the pump drive system to dispense the insulin medicine from the portable pump housing.

20. The system of claim 1 , wherein when the sensitivity of the occlusion detection system is adjusted, the control circuitry outputs a textual message via the user interface to notify a user of a change to the occlusion detection system.

21. The system of claim 19 , wherein the pump drive system comprises a battery powered actuator and a piston rod movable toward the insulin medicine.

22. The system of claim 21 , wherein the pump drive system comprises: the battery powered actuator including a rotational motor, a gear system actuated by the rotational motor, a ratchet mechanism including a ratchet wheel and a pawl that interacts with the gear system, a drive wheel configured to be rotated by the ratchet mechanism, and the piston rod that threadably engages with the drive wheel.

Assignments (19)
SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069870/0519 →
SECURITY INTEREST Recorded Jan 10, 2025
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069870/0456 →
SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069074/0001 →
SECURITY INTEREST Recorded Sep 30, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069073/0912 →
SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069030/0104 →
SECURITY INTEREST Recorded Sep 24, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069030/0296 →
SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069019/0188 →
SECURITY INTEREST Recorded Sep 23, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069019/0142 →
SECURITY INTEREST Recorded Sep 12, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 068948/0172 →
SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 068948/0324 →
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: BIGFOOT BIOMEDICAL, INC.
To: INSULET CORPORATION
Reel/Frame 063909/0826 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 062793/0316 →
SECURITY INTEREST Recorded Feb 10, 2023
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 062702/0145 →
SECURITY INTEREST Recorded Mar 12, 2021
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 055583/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2015
From: ASANTE SOLUTIONS, INC.
To: ASANTE LLC
Reel/Frame 036069/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2015
From: ASANTE LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 036066/0921 →
CHANGE OF NAME Recorded Jul 8, 2013
From: M2 GROUP HOLDINGS, INC.
To: ASANTE SOLUTIONS, INC.
Reel/Frame 030756/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2013
From: ESTES, MARK C.
To: M2 GROUP HOLDINGS, INC.
Reel/Frame 030748/0339 →